MicroRNAs  ||| S:0 E:10 ||| NNP
and  ||| S:10 E:14 ||| CC
future  ||| S:14 E:21 ||| JJ
therapeutic  ||| S:21 E:33 ||| JJ
applications  ||| S:33 E:46 ||| NNS
in  ||| S:46 E:49 ||| IN
cancer  ||| S:49 E:56 ||| NN
Every  ||| S:56 E:62 ||| DT
cellular  ||| S:62 E:71 ||| JJ
process  ||| S:71 E:79 ||| NN
is  ||| S:79 E:82 ||| VBZ
likely  ||| S:82 E:89 ||| JJ
to  ||| S:89 E:92 ||| TO
be  ||| S:92 E:95 ||| VB
regulated  ||| S:95 E:105 ||| VBN
by  ||| S:105 E:108 ||| IN
microRNAs  ||| S:108 E:118 ||| NNP
( ||| S:118 E:119 ||| -LRB-
miRNAs ||| S:119 E:125 ||| NNP
) ||| S:125 E:126 ||| -RRB-
,  ||| S:126 E:128 ||| ,
and  ||| S:128 E:132 ||| CC
an  ||| S:132 E:135 ||| DT
aberrant  ||| S:135 E:144 ||| JJ
expression  ||| S:144 E:155 ||| NN
signature  ||| S:155 E:165 ||| NN
of  ||| S:165 E:168 ||| IN
these  ||| S:168 E:174 ||| DT
small  ||| S:174 E:180 ||| JJ
non-coding  ||| S:180 E:191 ||| JJ
RNAs  ||| S:191 E:196 ||| NN
is  ||| S:196 E:199 ||| VBZ
a  ||| S:199 E:201 ||| DT
hallmark  ||| S:201 E:210 ||| NN
of  ||| S:210 E:213 ||| IN
several  ||| S:213 E:221 ||| JJ
diseases ||| S:221 E:229 ||| NNS
,  ||| S:229 E:231 ||| ,
including  ||| S:231 E:241 ||| VBG
cancer.  ||| S:241 E:249 ||| CD
miRNA  ||| S:249 E:255 ||| JJ
expression  ||| S:255 E:266 ||| NN
profiling  ||| S:266 E:276 ||| NN
by  ||| S:276 E:279 ||| IN
microarray  ||| S:279 E:290 ||| JJ
techniques  ||| S:290 E:301 ||| NNS
has  ||| S:301 E:305 ||| VBZ
provided  ||| S:305 E:314 ||| VBN
a  ||| S:314 E:316 ||| DT
powerful  ||| S:316 E:325 ||| JJ
tool  ||| S:325 E:330 ||| NN
to  ||| S:330 E:333 ||| TO
reveal  ||| S:333 E:340 ||| VB
the  ||| S:340 E:344 ||| DT
involvement  ||| S:344 E:356 ||| NN
of  ||| S:356 E:359 ||| IN
these  ||| S:359 E:365 ||| DT
tiny  ||| S:365 E:370 ||| JJ
molecules  ||| S:370 E:380 ||| NNS
in  ||| S:380 E:383 ||| IN
tumor  ||| S:383 E:389 ||| NN
development  ||| S:389 E:401 ||| NN
and  ||| S:401 E:405 ||| CC
progression ||| S:405 E:416 ||| NN
,  ||| S:416 E:418 ||| ,
showing  ||| S:418 E:426 ||| VBG
that  ||| S:426 E:431 ||| IN
they  ||| S:431 E:436 ||| PRP
are  ||| S:436 E:440 ||| VBP
differentially  ||| S:440 E:455 ||| VBN
expressed  ||| S:455 E:465 ||| VBN
in  ||| S:465 E:468 ||| IN
tumors  ||| S:468 E:475 ||| NNS
as  ||| S:475 E:478 ||| RB
compared  ||| S:478 E:487 ||| VBN
to  ||| S:487 E:490 ||| TO
normal  ||| S:490 E:497 ||| JJ
tissues ||| S:497 E:504 ||| NNS
.  ||| S:504 E:506 ||| .
Moreover ||| S:506 E:514 ||| RB
,  ||| S:514 E:516 ||| ,
specific  ||| S:516 E:525 ||| JJ
miRNA  ||| S:525 E:531 ||| JJ
signatures  ||| S:531 E:542 ||| NNS
have  ||| S:542 E:547 ||| VBP
been  ||| S:547 E:552 ||| VBN
associated  ||| S:552 E:563 ||| VBN
with  ||| S:563 E:568 ||| IN
histopathological  ||| S:568 E:586 ||| NN
and  ||| S:586 E:590 ||| CC
clinical  ||| S:590 E:599 ||| JJ
features ||| S:599 E:607 ||| NNS
,  ||| S:607 E:609 ||| ,
suggesting  ||| S:609 E:620 ||| VBG
a  ||| S:620 E:622 ||| DT
potential  ||| S:622 E:632 ||| JJ
role  ||| S:632 E:637 ||| NN
of  ||| S:637 E:640 ||| IN
these  ||| S:640 E:646 ||| DT
molecules  ||| S:646 E:656 ||| NN
as  ||| S:656 E:659 ||| IN
prognostic  ||| S:659 E:670 ||| NN
and  ||| S:670 E:674 ||| CC
predictive  ||| S:674 E:685 ||| JJ
markers ||| S:685 E:692 ||| NN
.  ||| S:692 E:694 ||| .
Focusing  ||| S:694 E:703 ||| VBG
then  ||| S:703 E:708 ||| RB
on  ||| S:708 E:711 ||| IN
their  ||| S:711 E:717 ||| PRP$
biological  ||| S:717 E:728 ||| JJ
effects  ||| S:728 E:736 ||| NNS
and  ||| S:736 E:740 ||| CC
role  ||| S:740 E:745 ||| NN
in  ||| S:745 E:748 ||| IN
cancer ||| S:748 E:754 ||| NN
,  ||| S:754 E:756 ||| ,
it  ||| S:756 E:759 ||| PRP
has  ||| S:759 E:763 ||| VBZ
been  ||| S:763 E:768 ||| VBN
shown  ||| S:768 E:774 ||| VBN
that  ||| S:774 E:779 ||| IN
miRNAs  ||| S:779 E:786 ||| NNP
can  ||| S:786 E:790 ||| MD
function  ||| S:790 E:799 ||| VB
as  ||| S:799 E:802 ||| IN
potential  ||| S:802 E:812 ||| JJ
oncogenes  ||| S:812 E:822 ||| NNS
or  ||| S:822 E:825 ||| CC
oncosuppressor  ||| S:825 E:840 ||| JJ
genes ||| S:840 E:845 ||| NNS
,  ||| S:845 E:847 ||| ,
depending  ||| S:847 E:857 ||| VBG
on  ||| S:857 E:860 ||| IN
the  ||| S:860 E:864 ||| DT
cellular  ||| S:864 E:873 ||| JJ
context  ||| S:873 E:881 ||| NN
and  ||| S:881 E:885 ||| CC
on  ||| S:885 E:888 ||| IN
the  ||| S:888 E:892 ||| DT
target  ||| S:892 E:899 ||| NN
genes  ||| S:899 E:905 ||| NNS
they  ||| S:905 E:910 ||| PRP
regulate ||| S:910 E:918 ||| VB
.  ||| S:918 E:920 ||| .
The  ||| S:920 E:924 ||| DT
possibility  ||| S:924 E:936 ||| NN
to  ||| S:936 E:939 ||| TO
modulate  ||| S:939 E:948 ||| VB
miRNA  ||| S:948 E:954 ||| JJ
expression  ||| S:954 E:965 ||| NN
either  ||| S:965 E:972 ||| CC
in  ||| S:972 E:975 ||| IN
vitro  ||| S:975 E:981 ||| NN
and  ||| S:981 E:985 ||| CC
in  ||| S:985 E:988 ||| IN
vivo  ||| S:988 E:993 ||| NN
by  ||| S:993 E:996 ||| IN
developing  ||| S:996 E:1007 ||| VBG
synthetic  ||| S:1007 E:1017 ||| JJ
pre-miRNA  ||| S:1017 E:1027 ||| JJ
molecules  ||| S:1027 E:1037 ||| NNS
or  ||| S:1037 E:1040 ||| CC
antisense  ||| S:1040 E:1050 ||| JJ
oligonucleotides  ||| S:1050 E:1067 ||| NNS
have  ||| S:1067 E:1072 ||| VBP
at  ||| S:1072 E:1075 ||| IN
the  ||| S:1075 E:1079 ||| DT
same  ||| S:1079 E:1084 ||| JJ
time  ||| S:1084 E:1089 ||| NN
provided  ||| S:1089 E:1098 ||| VBD
a  ||| S:1098 E:1100 ||| DT
powerful  ||| S:1100 E:1109 ||| JJ
tool  ||| S:1109 E:1114 ||| NN
to  ||| S:1114 E:1117 ||| TO
a  ||| S:1117 E:1119 ||| DT
deeper  ||| S:1119 E:1126 ||| JJR
comprehension  ||| S:1126 E:1140 ||| NN
of  ||| S:1140 E:1143 ||| IN
the  ||| S:1143 E:1147 ||| DT
molecular  ||| S:1147 E:1157 ||| JJ
mechanisms  ||| S:1157 E:1168 ||| NNS
regulated  ||| S:1168 E:1178 ||| VBN
by  ||| S:1178 E:1181 ||| IN
these  ||| S:1181 E:1187 ||| DT
molecules ||| S:1187 E:1196 ||| NN
,  ||| S:1196 E:1198 ||| ,
and  ||| S:1198 E:1202 ||| CC
suggested  ||| S:1202 E:1212 ||| VBD
the  ||| S:1212 E:1216 ||| DT
intriguing  ||| S:1216 E:1227 ||| JJ
and  ||| S:1227 E:1231 ||| CC
promising  ||| S:1231 E:1241 ||| JJ
perspective  ||| S:1241 E:1253 ||| NN
of  ||| S:1253 E:1256 ||| IN
their  ||| S:1256 E:1262 ||| PRP$
possible  ||| S:1262 E:1271 ||| JJ
use  ||| S:1271 E:1275 ||| NN
in  ||| S:1275 E:1278 ||| IN
therapy ||| S:1278 E:1285 ||| NN
.  ||| S:1285 E:1287 ||| .
Herein  ||| S:1287 E:1294 ||| VBG
we  ||| S:1294 E:1297 ||| PRP
review  ||| S:1297 E:1304 ||| VB
our  ||| S:1304 E:1308 ||| PRP$
current  ||| S:1308 E:1316 ||| JJ
knowledge  ||| S:1316 E:1326 ||| NN
about  ||| S:1326 E:1332 ||| IN
the  ||| S:1332 E:1336 ||| DT
involvement  ||| S:1336 E:1348 ||| NN
of  ||| S:1348 E:1351 ||| IN
miRNAs  ||| S:1351 E:1358 ||| JJ
in  ||| S:1358 E:1361 ||| IN
cancer ||| S:1361 E:1367 ||| NN
,  ||| S:1367 E:1369 ||| ,
and  ||| S:1369 E:1373 ||| CC
their  ||| S:1373 E:1379 ||| PRP$
potential  ||| S:1379 E:1389 ||| JJ
as  ||| S:1389 E:1392 ||| IN
diagnostic ||| S:1392 E:1402 ||| JJ
,  ||| S:1402 E:1404 ||| ,
prognostic  ||| S:1404 E:1415 ||| NN
and  ||| S:1415 E:1419 ||| CC
therapeutic  ||| S:1419 E:1431 ||| JJ
tools ||| S:1431 E:1436 ||| NNS
.  ||| S:1436 E:1438 ||| .
